Skip to main content
Fig. 2 | BMC Cancer

Fig. 2

From: Comparison of epidermal growth factor receptor tyrosine kinase inhibitors for patients with lung adenocarcinoma harboring different epidermal growth factor receptor mutation types

Fig. 2

Survival curves in lung adenocarcinoma patients harbouring EGFR mutations who received tyrosine kinase inhibitors. a Comparison of progression-free survival according to mutation type. b Comparison of overall survival according to mutation type. c Comparison of progression-free survival according to treatment regimen. d Comparison of overall survival according to treatment regimen

Back to article page
\